Commercial Credit Report for BioMark Diagnostics Inc

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for BioMark Diagnostics Inc is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	BioMark Diagnostics Inc
165-10551 Shellbridge Way
Phone: (604) 836-6950p:604 836-6950	Richmond, BC V6X 2W8 Canada	Ticker: BUXBUX

Business Summary

Biomark Diagnostics Inc. is an analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting investigational new drug (IND) and new drug application (NDA)-enabling studies. The Company is engaged in the cancer diagnostics using metabolites. The Company's metabolomics-based diagnostic assay allows cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement through liquid chromatography mass spectrometry (LC MS) in body fluids. This acetylation is performed by the enzyme, spermine/spermidine N-acetyl transferase (SSAT). SSAT is observed in various cancers, including lung, breast, prostate, melanoma and gastrointestinal (GI) cancers. The analysis of SSAT messenger ribonucleic acid (mRNA) levels in tissue samples allows determination of cancer type.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	IRA CQ Score	Moody's Rating	Fitch Rating	DBRS Rating	Morningstar Rating
Yes	Yes	-	-	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2019	3/31/2019	Yes	-	-	-	-

Industries

SIC Code	Description
2835	In vitro and in vivo diagnostic substances

Business Names

Business Name
20B
Biomark Cancer Systems Inc.
BUX

General Information

Outstanding Shares:	69,220,912	(As of 9/3/2019)
Stock Exchange:	CNQ
Fax Number:	(604) 836-6950

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN